Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 733958
                    [Title] => Roche lung cancer drug receives FDA approval
                    [Summary] => 
Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
                    [DatePublished] => 2011-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

OPTIMAL STUDY

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 733958
                    [Title] => Roche lung cancer drug receives FDA approval
                    [Summary] => 
Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
                    [DatePublished] => 2011-10-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche lung cancer drug receives FDA approval

October 6, 2011 - 12:00am

Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first-line therapy for people with advanced or metastatic non-small...

Science and Environment